PMF is classified as a multifactorial condition in which somatic variants in specific genes drive the myeloproliferative process. The packet identifies four associated genes: JAK2 (chromosome 9), CALR (chromosome 19), MPL (chromosome 1), and SH2B3 (chromosome 12). These genes encode proteins involved in blood cell signaling and proliferative regulation. The variants involved arise within blood-forming cells during an individual's lifetime rather than being inherited from parents in a simple Mendelian pattern, consistent with the multifactorial classification. Additional biological factors beyond these somatic drivers are also thought to influence disease onset and progression. The condition can result from variants in any of these four genes, and each may carry distinct phenotypic associations.

Diagnostic evaluation for PMF centers on bone marrow assessment, with fibrosis documented as an obligate pathological feature (Orphanet HPO data). Blood count abnormalities and clinical features including splenomegaly and hepatomegaly contribute to the diagnostic picture. Molecular assessment targeting variants in JAK2, CALR, and MPL—all identified in the packet's known_genes field—can support classification and differentiation from related myeloproliferative conditions. The packet does not enumerate specific diagnostic criteria or protocols; evaluation approaches are described in Orphanet, OMIM, and GARD source documentation.

The packet's orphan drug records identify two therapies with approved status for primary myelofibrosis. Fedratinib (INREBIC), developed by Impact Biomedicines/Celgene, holds approved orphan drug status for both primary and secondary myelofibrosis. Pacritinib (Vonjo), sponsored by Sobi, Inc., similarly holds approved status for primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. A dedicated approved_treatments field is absent from this packet, limiting strict FDA-approval framing per pipeline conventions; treatment information here is drawn from the orphan_drugs approved status records. Allogeneic stem cell transplantation is represented in active clinical trials in the packet (e.g., NCT06345495, NCT06674382), reflecting ongoing investigation of this procedural approach. Clinical management reflects disease risk stratification and symptom burden as characterized in the published literature.

A dedicated natural history or prognosis field is not present in this packet. The disease definition notes that clinical manifestations depend on the specific blood cell lineages affected. PMF follows a variable course across individuals, as reflected in the broad spectrum of phenotypic features and the range of treatment approaches under investigation. Prognosis information beyond the clinical context provided in the OMIM and Orphanet-sourced definition is not certified in this packet.

Primary myelofibrosis is an area of active clinical research. Among the trials documented in the packet, currently recruiting studies include NCT07357727, a Phase 3 evaluation of pelabresib (DAK539) combined with ruxolitinib, sponsored by Novartis Pharmaceuticals; NCT06345495, a Phase 2 study of high-dose ruxolitinib with allogeneic stem cell transplantation in patients with splenomegaly, sponsored by M.D. Anderson Cancer Center; NCT05714072, a Phase 1 study of ruxolitinib combined with abemaciclib, sponsored by Memorial Sloan Kettering Cancer Center; and NCT05320198, a Phase 1 study of DISC-0974 (RALLY-MF) for myelofibrosis-associated anemia, sponsored by Disc Medicine. The research landscape digest in the packet identifies 512 classified publications with gene therapy and biomarker research represented, and recent clinical trial publications documented.